Current situation of invasive fungal disease secondary to chemotherapy in leukemia children and progress of blinatumomab as a bridging therapy
Children with leukemia always experience severe bone marrow suppression following chemotherapy,significantly increasing their susceptibility to invasive fungal disease(IFD),which not only complicates treatment but also leads to higher fatality rates.Temporary interruption of chemotherapy during anti-infection treatment is suggested in order to restore immune function,but this may also results in leukemia relapse.Blinatumomab,a bispecific T-cell engager,has demonstrated benefits as a bridging therapy for children with leukemia and IFD.This article provides a comprehensive overview of the current landscape of IFD secondary to chemotherapy in leukemia children and the relevant researches on blinatumomab as a bridging therapeutic agent,so as to provide more ideas for its treatment.
NETL
NSTL
万方数据
